• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study.

作者信息

Duan Fangfang, Hua Xin, Lu Wei, Gui Xingxing, Xie Jingdun, Wang Xudong, Ma Yuyu, Zhai Wenyu, Xia Wen

机构信息

State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Department of Anesthesiology, Sun Yat-sen University Cancer Center, Guangzhou, China.

出版信息

Breast Cancer Res. 2025 Jul 21;27(1):135. doi: 10.1186/s13058-025-02088-5.

DOI:10.1186/s13058-025-02088-5
PMID:40691796
Abstract
摘要

相似文献

1
Trastuzumab deruxtecan in patients with active brain metastases from HER2-positive/low metastatic breast cancer: a retrospective multicenter real-world study.曲妥珠单抗德鲁替康用于HER2阳性/低表达转移性乳腺癌伴活动性脑转移患者：一项回顾性多中心真实世界研究
Breast Cancer Res. 2025 Jul 21;27(1):135. doi: 10.1186/s13058-025-02088-5.
2
Trastuzumab Deruxtecan in Previously Treated HER2-Low Metastatic Breast Cancer: Real-World Multicentric Study in the Portuguese Population.曲妥珠单抗德鲁昔单抗用于既往治疗过的HER2低表达转移性乳腺癌：葡萄牙人群的真实世界多中心研究
Cancers (Basel). 2025 Jun 9;17(12):1911. doi: 10.3390/cancers17121911.
3
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis.曲妥珠单抗德鲁替康用于人表皮生长因子受体2阳性乳腺癌脑转移：一项系统评价和更新的荟萃分析。
Cancer Treat Rev. 2025 Feb;133:102882. doi: 10.1016/j.ctrv.2025.102882. Epub 2025 Jan 6.
4
Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.在一个大型转移性乳腺癌患者真实世界数据库中，根据生物标志物状态、治疗线数和既往是否接受过戈沙妥珠单抗，分析曲妥珠单抗德鲁替康的治疗结果。
ESMO Open. 2025 Jun 17;10(7):105330. doi: 10.1016/j.esmoop.2025.105330.
5
Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study.预测曲妥珠单抗德鲁昔单抗治疗HER2表达转移性乳腺癌疗效的预后指数：一项真实世界多中心研究
Oncologist. 2025 Aug 4;30(8). doi: 10.1093/oncolo/oyaf174.
6
Long Durable Response With Trastuzumab Deruxtecan Monotherapy in a Triple-Negative Metastatic Breast Cancer Patient With Human Epidermal Growth Factor Receptor 2 Mutation: A Long-Term Follow-Up and Literature Review.曲妥珠单抗德鲁替康单药治疗人表皮生长因子受体2突变的三阴性转移性乳腺癌患者的长期持久反应：长期随访及文献综述
J Med Cases. 2025 Jun 16;16(6):212-221. doi: 10.14740/jmc5136. eCollection 2025 Jun.
7
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.曲妥珠单抗 deruxtecan 用于美国和欧洲的曲妥珠单抗治疗后疾病进展的 HER2 阳性晚期胃或胃食管交界处癌患者（DESTINY-Gastric02）：一项单臂、2 期研究的主要和更新分析。
Lancet Oncol. 2023 Jul;24(7):744-756. doi: 10.1016/S1470-2045(23)00215-2. Epub 2023 Jun 14.
8
Brain Metastases From HER2 Breast Cancer That Achieved Complete Response With Trastuzumab Deruxtecan Without Any Local Treatment.经曲妥珠单抗德鲁昔单抗治疗后达到完全缓解且未接受任何局部治疗的HER2阳性乳腺癌脑转移病例
Cureus. 2025 May 29;17(5):e85011. doi: 10.7759/cureus.85011. eCollection 2025 May.
9
Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report.使用安罗替尼和曲妥珠单抗德鲁昔单抗治疗HER2阳性乳腺癌脑转移：一例报告
Int J Womens Health. 2024 Jul 29;16:1277-1283. doi: 10.2147/IJWH.S472628. eCollection 2024.
10
Long-term survival in a patient with brain metastases and leptomeningeal disease of breast cancer: a case report of a patient receiving trastuzumab-deruxtecan.一名患有乳腺癌脑转移和软脑膜疾病患者的长期生存：一例接受曲妥珠单抗-德曲妥珠单抗治疗患者的病例报告
Arch Gynecol Obstet. 2025 Jul 8. doi: 10.1007/s00404-025-08096-2.

本文引用的文献

1
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.TUXEDO-4：曲妥珠单抗-德曲妥珠单抗治疗伴有新发性或进展性脑转移的HER2低表达乳腺癌的II期研究。
Future Oncol. 2025 Apr;21(9):1065-1073. doi: 10.1080/14796694.2025.2470604. Epub 2025 Feb 28.
2
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan.曲妥珠单抗德鲁替康治疗乳腺癌脑转移的真实世界疗效分析
NPJ Precis Oncol. 2025 Jan 22;9(1):22. doi: 10.1038/s41698-025-00801-3.
3
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
曲妥珠单抗德鲁昔单抗用于伴或不伴脑转移的HER2阳性晚期乳腺癌：一项3b/4期试验
Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13.
4
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases.曲妥珠单抗德鲁替康用于伴脑转移的人表皮生长因子受体2（HER2）阳性转移性乳腺癌患者的汇总分析。
Ann Oncol. 2024 Dec;35(12):1169-1180. doi: 10.1016/j.annonc.2024.08.2347. Epub 2024 Sep 5.
5
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases.曲妥珠单抗-德曲妥珠单抗用于HER2阳性且伴有活动性脑转移的乳腺癌患者的II期TUXEDO-1试验的最终结果分析。
Neuro Oncol. 2024 Dec 5;26(12):2305-2315. doi: 10.1093/neuonc/noae123.
6
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.曲妥珠单抗-德鲁替康与医生选择的治疗方案用于治疗既往治疗的亚洲 HER2 低表达不可切除/转移性乳腺癌患者：DESTINY-Breast04 研究的亚组分析。
Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17.
7
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新在随机 DESTINY-Breast03 试验中用于 HER2 阳性转移性乳腺癌伴脑转移患者的比较。
ESMO Open. 2024 May;9(5):102924. doi: 10.1016/j.esmoop.2024.102924. Epub 2024 Apr 24.
8
"Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper".“曲妥珠单抗替西替尼在 HER2 阳性转移性乳腺癌新临床治疗方案中的定位：意大利和西班牙共识文件”。
Breast. 2024 Aug;76:103742. doi: 10.1016/j.breast.2024.103742. Epub 2024 May 16.
9
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial.单纯全脑放疗与贝伐珠单抗、依托泊苷和顺铂序贯治疗未经治疗的乳腺癌脑转移：一项随机临床试验。
JAMA Oncol. 2024 Mar 1;10(3):325-334. doi: 10.1001/jamaoncol.2023.5456.
10
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).曲妥珠单抗德鲁替康治疗HER2阳性乳腺癌伴脑转移和/或软脑膜疾病患者（ROSET-BM）。
NPJ Breast Cancer. 2023 Oct 11;9(1):82. doi: 10.1038/s41523-023-00584-5.